|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.31 USD | +1.45% |
|
-6.23% | -9.81% |
| Capitalization | 6.58B 5.62B 5.22B 4.9B 9.08B 602B 9.73B 59.91B 23.71B 285B 24.66B 24.16B 1,040B | P/E ratio 2025 * |
60.3x | P/E ratio 2026 * | 45.9x |
|---|---|---|---|---|---|
| Enterprise value | 6.5B 5.55B 5.16B 4.84B 8.97B 595B 9.61B 59.17B 23.41B 281B 24.36B 23.86B 1,027B | EV / Sales 2025 * |
2.77x | EV / Sales 2026 * | 2.2x |
| Free-Float |
84.41% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Hims & Hers Health, Inc.
| 1 day | +1.47% | ||
| 1 week | -6.23% | ||
| Current month | -9.81% | ||
| 1 month | -16.45% | ||
| 3 months | -38.30% | ||
| 6 months | -41.44% | ||
| Current year | -9.81% |
| 1 week | 27.96 |  | 31.82 |
| 1 month | 27.96 | | 36.45 |
| Current year | 27.96 | | 36.45 |
| 1 year | 23.97 | | 72.98 |
| 3 years | 5.65 | | 72.98 |
| 5 years | 2.72 | | 72.98 |
| 10 years | 2.72 | | 72.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andrew Dudum
CEO | Chief Executive Officer | 37 | 19/01/2021 |
Oluyemi Okupe
DFI | Director of Finance/CFO | 40 | 23/01/2022 |
Mo Elshenawy
CTO | Chief Tech/Sci/R&D Officer | 52 | 07/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Dudum
CHM | Chairman | 37 | 19/01/2021 |
Delos Cosgrove
BRD | Director/Board Member | 85 | 19/01/2021 |
David Wells
BRD | Director/Board Member | 54 | 19/01/2021 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.29% | 0.02% | 300 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.45% | -6.23% | -1.46% | +283.81% | 6.58B | |
| +2.84% | -2.14% | -35.32% | -76.90% | 1.09B | |
| +5.28% | +3.83% | - | - | 905M | |
| +5.10% | +4.96% | +27.22% | +450.61% | 633M | |
| 0.00% | +18.56% | -29.49% | +1,170.88% | 556M | |
| +4.40% | -0.42% | -53.94% | -93.88% | 74.33M | |
| +0.46% | +0.46% | -56.00% | -92.09% | 51.13M | |
| Average | +2.55% | +0.23% | -24.83% | +273.74% | 1.41B | |
| Weighted average by Cap. | +2.14% | -4.77% | -6.04% | +301.34% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.35B 2.01B 1.86B 1.75B 3.24B 215B 3.47B 21.37B 8.46B 102B 8.8B 8.62B 371B | 2.76B 2.36B 2.19B 2.06B 3.82B 253B 4.09B 25.18B 9.96B 120B 10.37B 10.15B 437B |
| Net income | 120M 102M 95.12M 89.21M 166M 10.98B 177M 1.09B 432M 5.19B 449M 440M 18.95B | 147M 126M 117M 109M 203M 13.46B 217M 1.34B 530M 6.36B 551M 540M 23.23B |
| Net Debt | -80.84M -69.12M -64.16M -60.18M -112M -7.41B -120M -736M -291M -3.5B -303M -297M -12.78B | -491M -420M -390M -365M -678M -44.96B -726M -4.47B -1.77B -21.25B -1.84B -1.8B -77.61B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/01/26 | 29.28 $ | +1.35% | 4,274,954 |
| 21/01/26 | 28.89 $ | -5.19% | 27,909,630 |
| 20/01/26 | 30.47 $ | -2.90% | 16,471,846 |
| 16/01/26 | 31.38 $ | +0.48% | 14,591,241 |
| 15/01/26 | 31.23 $ | -0.29% | 13,666,261 |
Delayed Quote Nyse, January 22, 2026 at 04:20 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HIMS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition